Shreyas Bhat1, Nilesh Gardi1,2, Sujata Hake1, Nirupama Kotian1, Sharada Sawant1, Sadhana Kannan3, Vani Parmar4,2, Sangeeta Desai5,2, Amit Dutt1,2, Narendra N Joshi6,7. 1. Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, Maharashtra, 410210, India. 2. Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, Maharashtra, India. 3. Epidemiology and Clinical Trials Unit, Clinical Research Centre, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, Maharashtra, 410210, India. 4. Department of Surgical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, 400012, India. 5. Department of Pathology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, 400012, India. 6. Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, Maharashtra, 410210, India. njoshi@actrec.gov.in. 7. Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, Maharashtra, India. njoshi@actrec.gov.in.
Abstract
PURPOSE: Pro-inflammatory cytokines such as Interleukin-17A (IL17A) and Interleukin-32 (IL32), known to enhance natural killer and T cell responses, are also elevated in human malignancies and linked to poor clinical outcomes. To address this paradox, we evaluated relation between IL17A and IL32 expression and other inflammation- and T cell response-associated genes in breast tumors. METHODS: TaqMan-based gene expression analysis was carried out in seventy-eight breast tumors. The association between IL17A and IL32 transcript levels and T cell response genes, ER status as well as lymph node status was also examined in breast tumors from TCGA dataset. RESULTS: IL17A expression was detected in 32.7% ER-positive and 84.6% ER-negative tumors, with higher expression in the latter group (26.2 vs 7.1-fold, p < 0.01). ER-negative tumors also showed higher expression of IL32 as opposed to ER-positive tumors (8.7 vs 2.5-fold, p < 0.01). Expression of both IL17A and IL32 genes positively correlated with CCL5, GNLY, TBX21, IL21 and IL23 transcript levels (p < 0.01). Amongst ER-positive tumors, higher IL32 expression significantly correlated with lymph node metastases (p < 0.05). Conversely, in ER-negative subtype, high IL17A and IL32 expression was seen in patients with negative lymph node status (p < 0.05). Tumors with high IL32 and IL17A expression showed higher expression of TH1 response genes studied, an observation validated by similar analysis in the TCGA breast tumors (n=1041). Of note, these tumors were characterized by low expression of a potentially immunosuppressive isoform of IL32 (IL32γ). CONCLUSION: These results suggest that high expression of both IL17A and IL32 leads to enhancement of T cell responses. Our study, thus, provides basis for the emergence of strong T cell responses in an inflammatory milieu that have been shown to be associated with better prognosis in ER-negative breast cancer.
PURPOSE: Pro-inflammatory cytokines such as Interleukin-17A (IL17A) and Interleukin-32 (IL32), known to enhance natural killer and T cell responses, are also elevated in human malignancies and linked to poor clinical outcomes. To address this paradox, we evaluated relation between IL17A and IL32 expression and other inflammation- and T cell response-associated genes in breast tumors. METHODS: TaqMan-based gene expression analysis was carried out in seventy-eight breast tumors. The association between IL17A and IL32 transcript levels and T cell response genes, ER status as well as lymph node status was also examined in breast tumors from TCGA dataset. RESULTS: IL17A expression was detected in 32.7% ER-positive and 84.6% ER-negative tumors, with higher expression in the latter group (26.2 vs 7.1-fold, p < 0.01). ER-negative tumors also showed higher expression of IL32 as opposed to ER-positive tumors (8.7 vs 2.5-fold, p < 0.01). Expression of both IL17A and IL32 genes positively correlated with CCL5, GNLY, TBX21, IL21 and IL23 transcript levels (p < 0.01). Amongst ER-positive tumors, higher IL32 expression significantly correlated with lymph node metastases (p < 0.05). Conversely, in ER-negative subtype, high IL17A and IL32 expression was seen in patients with negative lymph node status (p < 0.05). Tumors with high IL32 and IL17A expression showed higher expression of TH1 response genes studied, an observation validated by similar analysis in the TCGA breast tumors (n=1041). Of note, these tumors were characterized by low expression of a potentially immunosuppressive isoform of IL32 (IL32γ). CONCLUSION: These results suggest that high expression of both IL17A and IL32 leads to enhancement of T cell responses. Our study, thus, provides basis for the emergence of strong T cell responses in an inflammatory milieu that have been shown to be associated with better prognosis in ER-negative breast cancer.
Entities:
Keywords:
Breast cancer; Gene expression; Interleukin-17A; Interleukin-32; Lymph node status
Authors: Muneo Numasaki; Jun-ichi Fukushi; Mayumi Ono; Satwant K Narula; Paul J Zavodny; Toshio Kudo; Paul D Robbins; Hideaki Tahara; Michael T Lotze Journal: Blood Date: 2002-10-31 Impact factor: 22.113
Authors: Claudia A Nold-Petry; Ina Rudloff; Yvonne Baumer; Menotti Ruvo; Daniela Marasco; Paolo Botti; Laszlo Farkas; Steven X Cho; Jarod A Zepp; Tania Azam; Hannah Dinkel; Brent E Palmer; William A Boisvert; Carlyne D Cool; Laima Taraseviciene-Stewart; Bas Heinhuis; Leo A B Joosten; Charles A Dinarello; Norbert F Voelkel; Marcel F Nold Journal: J Immunol Date: 2013-12-11 Impact factor: 5.422
Authors: Leonel F Hernandez-Aya; Mariana Chavez-Macgregor; Xiudong Lei; Funda Meric-Bernstam; Thomas A Buchholz; Limin Hsu; Aysegul A Sahin; Kim-Anh Do; Vicente Valero; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: Jeong Su Park; Sunyi Lee; Ae Lee Jeong; Sora Han; Hye In Ka; Jong-Seok Lim; Myung Sok Lee; Do-Young Yoon; Jeong-Hyung Lee; Young Yang Journal: Cancer Lett Date: 2014-11-06 Impact factor: 8.679
Authors: Fabien Reyal; Martin H van Vliet; Nicola J Armstrong; Hugo M Horlings; Karin E de Visser; Marlen Kok; Andrew E Teschendorff; Stella Mook; Laura van 't Veer; Carlos Caldas; Remy J Salmon; Marc J van de Vijver; Lodewyk F A Wessels Journal: Breast Cancer Res Date: 2008-11-13 Impact factor: 6.466
Authors: Yvette J E Sloot; Katrin Rabold; Thomas Ulas; Dennis M De Graaf; Bas Heinhuis; Kristian Händler; Joachim L Schultze; Mihai G Netea; Johannes W A Smit; Leo A B Joosten; Romana T Netea-Maier Journal: Cell Oncol (Dordr) Date: 2019-06-14 Impact factor: 6.730
Authors: Bassel Dawod; Jinghua Liu; Simon Gebremeskel; Chi Yan; Antonia Sappong; Brent Johnston; David W Hoskin; Jean S Marshall; Jun Wang Journal: Sci Rep Date: 2020-08-07 Impact factor: 4.379